scholarly journals Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment

2021 ◽  
Vol 143 ◽  
pp. 112195
Author(s):  
Jennifer J. Lin ◽  
Catrina M. Loucks ◽  
Jessica N. Trueman ◽  
Britt I. Drögemöller ◽  
Galen E.B. Wright ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Hepatitis C Treatment ◽  
Novel Variant ◽  
Glycophorin C

Real-world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic hepatitis C treatment

2015 ◽  
Vol 53 (08) ◽  
Author(s):  
P Buggisch ◽  
J Petersen ◽  
K Wursthorn ◽  
A Gauthier ◽  
P Atanasov
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Real World ◽  
Hepatitis C Treatment

scholarly journals Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population

2016 ◽  
Vol 4 ◽  
pp. 133-137
Author(s):  
Anna Piekarska ◽  
Ewa Koślińska-Berkan ◽  
Kamila Wójcik ◽  
Anna Skubała ◽  
Maciej Jabłkowski ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Protease Inhibitors ◽  
Chronic Hepatitis C ◽  
First Generation ◽  
Real Life ◽  
Direct Costs ◽  
Hepatitis C Treatment

scholarly journals CHRONIC HEPATITIS C TREATMENT IN 2015

1969 ◽  
Vol 4 (2) ◽  
pp. 482
Author(s):  
AZIZ AHMAD
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
National Level ◽  
Progressive Damage ◽  
Hepatitis C Treatment

On a national level over 5% of the population isestimated to be infected with the hepatitis C virus(HCV), which corresponds to a prevalentpopulation of >70 million people with chronicinfection. For many patients who becomechronically infected, HCV causes slow,progressive damage to the liver and represents oneof the leading causes of cirrhosis andhepatocellular carcinoma (HCC).

Sign in / Sign up

Export Citation Format

Share Document